Pinned Tweet
Scorpion Capital just dropped a 297-page short report on $ABVX, comparing obefazimod to DDT, dioxins, and livestock dewormer.
NEW: We are short $ABVX Abivax SA - a biotech fraud for the ages. Report now live on our site, along with four scientific abstracts based upon our laboratory experiments. An 11-month investigation, our most intensive research to date.
Adam Yusim retweeted
Scorpion calls the $ABVX obefazimod program a “fraud.” I went through the numbers behind that allegation. Start with the two that do the most work in the headline: 8.4× and 4×.
The 8.4× tells us how far obefazimod’s UVA absorption exceeded a screening threshold for further photosafety assessment. Scorpion’s experiment did not measure damage to human skin, tumor formation or cancer risk. As far back as 2022, Abivax’s public protocol disclosed preclinical phototoxicity of the metabolite and called for dermatologic surveillance. That risk was under investigation four years before Scorpion published its report.
The 4× comes from 4 nonmelanoma skin cancers among 195 patients on 50 mg, versus 1/192 on placebo, over 44 weeks of randomized maintenance. At 25 mg, it was 1/193. One detail matters: the placebo patient who developed skin cancer had received 50 mg during induction. Establishing whether the drug raises long-term cancer risk takes far more patients, years of exposure and an appropriate comparator. Scorpion also presents no evidence of oncogenic virus reactivation in these cases. Its own hypothesis centers on UVA exposure.
Obefazimod’s efficacy in ulcerative colitis has been demonstrated. In two separate Phase 3 induction trials, clinical remission on 50 mg versus placebo was 21.7% vs 2.5% and 19.8% vs 6.3%. In the third Phase 3 trial, among induction responders, 50.8% on 25 mg and 51.3% on 50 mg were in remission at week 44, versus 10.4% on placebo. Endoscopy confirmed the benefit as well.
If Scorpion is going to call three Phase 3 trials a fraud, show us which clinical data were falsified and how correcting them changes the result. I couldn’t find that evidence in 297 pages.
We added to our $ABVX position at $65.
Continued: Yet Abivax already completed a positive Pre-NDA interaction with the FDA on July 30, 2026. A Pre-NDA meeting is specifically where the agency audits whether the clinical pharmacology, nonclinical, and Phase 3 packages are complete enough to file. $ABVX
Replying to @AdamYusimBio
Finally, notice the glaring regulatory omission. Scorpion predicts an FDA ambush over "missing" PK, ADME, and DDI studies. $ABVX
The only items that actually deserve investor focus ahead of the NDA are the clinical back-half questions: country-level sensitivity data outside China and Ukraine, full ICH S10 photosafety and skin lesion adjudication, and the complete FDA clinical pharmacology review. $ABVX
1
341
Everything else is noise designed to help a short seller cover on day one. $ABVX
1
325
After digging deeper into the math, lab screenshots, and footnotes of Scorpion Capital's $ABVX report, the biggest flaws aren't in the loud headlines. They are buried in the fine print where Scorpion's own data directly contradicts its thesis. 🧵
Tazi's 2003 paper (p. 54): Scorpion calls a 2023 JCB "Retract and Replace" notice a sinister fraud where "ghost co-authors vanished," yet the pasted notice shows a 20-year-old plasmid error (S99P) where JCB upheld and republished the paper's core conclusions. $ABVX
1
1
353
Finally, notice the glaring regulatory omission. Scorpion predicts an FDA ambush over "missing" PK, ADME, and DDI studies. $ABVX




